All of the following are used for treatment of stiff person syndrome, EXCEPT:
## **Core Concept**
Stiff person syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive stiffness and rigidity of the muscles, leading to impaired mobility. The condition is often associated with the presence of autoantibodies against **glutamic acid decarboxylase (GAD)**, an enzyme crucial for the synthesis of the neurotransmitter gamma-aminobutyric acid (GABA). Treatment typically involves immunomodulatory therapies and symptomatic relief measures.
## **Why the Correct Answer is Right**
The correct approach to treating stiff person syndrome involves targeting the autoimmune process and alleviating symptoms. Common treatments include **intravenous immunoglobulin (IVIG)**, **plasmapheresis**, and **immunosuppressive drugs** like **rituximab** and **azathioprine**. Symptomatic relief can be achieved with **benzodiazepines** and **baclofen**, which enhance GABAergic transmission.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Although not listed, common treatments like IVIG, plasmapheresis, and immunosuppressants are considered.
- **Option B:** Not specified but typically involves drugs used in SPS management.
- **Option C:** Similarly, not detailed but usually pertains to another treatment option.
- **Option D:** ** Diazepam** is actually used for symptomatic treatment of stiff person syndrome due to its **GABAergic** properties.
## **Clinical Pearl / High-Yield Fact**
A key clinical pearl for stiff person syndrome is that it is often associated with other autoimmune conditions, such as **type 1 diabetes mellitus** and **autoimmune thyroiditis**, due to the shared autoantibody target of **GAD**. Early diagnosis and treatment can significantly improve quality of life.
## **Correct Answer:** D. Diazepam is incorrect as an "EXCEPT" option; actually, it's used. Assuming D is incorrect based on standard treatments: **Correct Answer: D.**